STARWOOD-HOTELS
From the Arabian Hotel Investment Conference (AHIC) in Dubai, Starwood Hotels & Resorts Worldwide, Inc. (NYSE:HOT) today announced that it is on track to grow its portfolio in the Middle East to 100 hotels by 2020. This follows five new deal signings that will add over 1,200 rooms in the UAE, Saudi Arabia and Qatar. Starwood will also open five hotels in 2016 across the United Arab Emirates, Saudi Arabia and Qatar.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160427005694/en/
“The Middle East continues to be one of Starwood’s fastest growing markets and we are immensely committed to the trust that owners have in our world-class brands,” said Michael Wale, President of Starwood, Europe, Africa and Middle East. “Our long-established presence in the region, and the value we deliver, has set us ahead to further expand our footprint and strengthen our guest loyalty.”
“We continue to strengthen Starwood's leadership position in the Middle East through an aggressive growth strategy that will increase our footprint by 75% in the next five years," said Simon Turner, President of Global Development for Starwood Hotels & Resorts Worldwide, Inc. "Our flexible development approach, differentiated brands, loyal customer base and proven ability to drive asset value has made Starwood the ideal partner for developers in the region."
Starwood’s newest hotel signings in the region include:
A Luxury Collection Hotel and Le Méridien in Lusail, Qatar
These
signings come on the heels of Starwood’s Europe, Africa and Middle East
leadership conference in March in Doha, where the company operates some
of the capital’s most iconic hotels. Starwood will double its current
portfolio in Qatar and diversify its brand presence when these two
hotels open in Lusail by the end of 2018.
Owned by United Developers Company LLC., the two hotels will add 650 rooms in Qatar's city of the future that will host the World Cup 2022's opening and closing ceremonies. Part of a Parisian inspired mixed-use development, Place Vendôme, the hotels will be directly connected to a shopping center featuring more than 400 different fashion and food and beverage outlets. The Luxury Collection hotel will mark the entry of the brand into Qatar, offering global explorers a unique gateway to this visionary destination. The Le Méridien hotel will be the second property from the Parisian-born brand in Qatar and will feature signature features such as Le Méridien Hub, an innovative reinterpretation of the traditional hotel lobby.
Four Points by Sheraton Jeddah Tahlia, Saudi Arabia
Scheduled
to open in 2020, the Four Points by Sheraton Jeddah will be the first
Four Points to open in the city. The hotel will feature 180 rooms and
will be ideally located close to Tahlia Street, Jeddah’s upscale
shopping district. The hotel will appeal to leisure and business
travellers with over 3,000 square feet of meeting space and fitness
facilities, including an outdoor pool.
Four Points by Sheraton Unaizah, Saudi Arabia
Starwood will
make its entry into Unaizah in Saudi Arabia with the signing of Four
Points by Sheraton Unaizah. Signed with Unaizah Investment Company, the
hotel will open in 2020 and feature an urban-resort feel attracting
leisure and business travellers with its 130 rooms including chalets and
villas, health and recreation facilities with multiple swimming pools, a
spa and nearly 9,000 square feet of meeting space.
Four Points by Sheraton Ras Al Khaimah, UAE
Starwood
continues to expand its footprint in the UAE with its first hotel in the
emirate of Ras Al Khaimah. Signed with Hamarain Real Estate LLC, Four
Points by Sheraton Ras Al Khaimah will offer 300 rooms and serviced
apartments and four food and beverage outlets when it opens in 2019. The
signing underlines Ras Al Khaimah’s plan to enhance the destination and
diversify its hotel portfolio.
All three Four Points by Sheraton properties will reflect the brand’s promise to provide what matters most to today’s independent travellers, the hotel will offer all of the brand’s defining touches, including the signature Four Comfort bed and complimentary bottled water, free Wi-Fi in all public areas, an energising breakfast, the brand’s signature Best Brews™ programme as well as food and beverage outlets.
“The new deal signings represent the immense development opportunities this region continues to offer for our 10 distinct lifestyle brands in established and fast-growing markets,” said Neil George, Senior Vice President Acquisition & Development, Starwood Hotels & Resorts, Africa & Middle East. “In particular, our mid-markets brands continue to capitalise on the strong demand for affordable hospitality in the region and we also continue to see steady growth across our luxury and upper-upscale brands, allowing us to strengthen and diversify our brand portfolio in the Middle East.”
2016 Opening Highlights:
Starwood will expand its regional
footprint to nearly 60 properties and over 17,000 rooms this year with
five openings in the Middle East. Following the recent debut of The
Westin Doha Hotel & Spa
, the brand’s entry to Qatar, Starwood
will open:
- W Dubai Al Habtoor City and The Westin Dubai Al Habtoor City which, together with The St. Regis Dubai which opened last November, form Starwood’s largest hospitality project in the Middle East. This double debut will mark the entry of the W Hotels brand into the UAE and the launch of the largest Westin hotel in the Middle East with over 1,000 rooms. Both hotels are scheduled to open in Q2.
- Launch of the Aloft brand in Saudi Arabia with the openings of Aloft Riyadh and Aloft Dhahran in Q3. Together the hotels will add over 500 rooms in The Kingdom.
- Re-opening of the Sheraton Oman in Q3 following extensive renovations of its rooms and public spaces, refreshed food and beverage outlets and extension of one of the largest ballrooms in the country.
Starwood will grow its footprint by over 75 percent in the next five years with a robust pipeline of more than 40 hotels and over 12,000 rooms across its luxury, upper-upscale and mid-market brands.
Starwood’s mid-market brands – Aloft, Four Points by Sheraton and Element – continue to fuel growth for the company in the Middle East, illustrating the strong demand for reliable and affordable hospitality in the region. Together, the three brands represent more than 50 percent of the company’s growth pipeline in the region.
Starwood also continues to see strong growth opportunities for its luxury brands and will double its luxury hotels portfolio in the Middle East with ten new openings across the St. Regis, Luxury Collection and W Hotels brands. The company’s upper-upscale brands - Sheraton, Le Méridien and Westin – which currently make up 70 percent of its current portfolio in the Middle East – will account for nearly 50 percent of the future footprint with seven new projects scheduled to open by 2020.
-End-
About Starwood Hotels & Resorts Worldwide, Inc.
Starwood
Hotels & Resorts Worldwide, Inc.
is one of the leading hotel and
leisure companies in the world with nearly 1,300 properties in some 100
countries and over 188,000 employees at its owned and managed
properties. Starwood is a fully integrated owner, operator and
franchisor of hotels, resorts and residences under the renowned brands: St.
Regis
®
, The
Luxury Collection
®
, W
®
,
Westin
®
,
Le
Méridien
®
, Sheraton
®
,
Tribute
Portfolio
™, Four
Points
®
by Sheraton, Aloft
®
,
Element
®
,
along with an expanded partnership with Design
Hotels
™
. The Company also boasts one of the industry’s
leading loyalty programs, Starwood
Preferred Guest
(SPG®
). Visit www.starwoodhotels.com
for more information and stay connected @starwoodbuzz on Twitter
and Instagram
and facebook.com/Starwood.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160427005694/en/
Contact:
Starwood
Chandan Belani, Tel: +9714 307 9919
Regional Director
of Communications, Middle East
Chandan.Belani@starwoodhotels.com
or
ASDA’A
Burson-Marsteller
Tryphena Greenwood or Dana Sleiman
Tel:
971-4-4507600
Starwood@bm.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom